Screening for second malignancies in mycosis fungoides: Non‐Hodgkin lymphoma, Hodgkin lymphoma, lung cancer, bladder cancer, and melanoma

2021 ◽  
Author(s):  
Amrita Goyal ◽  
Daniel O’Leary ◽  
Kavita Goyal ◽  
Nathan Rubin ◽  
Murali Janakiram
Keyword(s):  
Lung Cancer ◽  
Bladder Cancer ◽  
Hodgkin Lymphoma ◽  
Mycosis Fungoides ◽  
Second Malignancies ◽  
Non Hodgkin Lymphoma

Trends in use of primary prophylactic colony stimulating factors and neutropenia-related hospitalization in commercially insured patients receiving myelosuppressive chemotherapy in the United States: 2005–2017

2020 ◽  
pp. 107815522091577 ◽  
Author(s):  
Jennifer R Schenfeld ◽  
Corina W Bennett ◽  
Shuling Li ◽  
Lucy J DeCosta ◽  
Renee R Jaramillo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Febrile Neutropenia ◽  
Hodgkin Lymphoma ◽  
Colony Stimulating Factor ◽  
Myelosuppressive Chemotherapy ◽  
Colony Stimulating Factors ◽  
Non Hodgkin Lymphoma ◽  
Insured Patients ◽  
Stimulating Factor

Purpose Describe temporal changes in use of myelosuppressive chemotherapy, primary prophylactic colony-stimulating factor, and neutropenia-related hospitalization, in commercially insured patients. Methods Using a large commercial administrative database, we identified annual cohorts of adult patients diagnosed with breast or lung cancer, or non-Hodgkin lymphoma and initiating myelosuppressive chemotherapy during 2005–2017. We described yearly changes in proportions of myelosuppressive chemotherapy by febrile neutropenia risk category (high, intermediate, unclassified) and proportion of prophylactic colony-stimulating factor use and unadjusted incidence of neutropenia-related hospitalization in the first cycle of myelosuppressive chemotherapy. Results Annual cohorts included 4383–5888 eligible patients during 2005–2017. The proportion of eligible patients aged ≥ 65 years increased from 26.0% in 2005 to 58.2% in 2017. Myelosuppressive chemotherapy use with regimens with high risk for febrile neutropenia increased from 15.1% in 2005 to 31.0% in 2017; and regimens with intermediate risk for febrile neutropenia decreased from 63.7% to 48.1% in 2017. Prophylactic colony-stimulating factor use increased from 41.6% in 2005 to 54.3% in 2017. Crude incidence of neutropenia-related hospitalization for all cancers increased from 2.0% to 3.1%, with a substantial increase in neutropenia-related hospitalization observed among non-Hodgkin lymphoma patients (2.8% to 8.5%) during 2005–2017. Conclusion Among adult patients with breast and lung cancer, and non-Hodgkin lymphoma receiving myelosuppressive chemotherapy, use of regimens with high risk for febrile neutropenia increased, as did the use of prophylactic colony-stimulating factors after 2005. Incidence of neutropenia-related hospitalization increased slightly, particularly among non-Hodgkin lymphoma patients. Further studies are required to understand this increasing trend of neutropenia-related hospitalization, changing patient-level risk factors, and febrile neutropenia management.

scholarly journals Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study group

Haematologica ◽  
2020 ◽  
pp. haematol.2019.244780
Author(s):  
Olga Moser ◽  
Martin Zimmermann ◽  
Ulrike Meyer ◽  
Wolfram Klapper ◽  
Ilske Oschlies ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Study Group ◽  
Second Malignancies ◽  
Non Hodgkin Lymphoma

Abstract LB-184: Risk factors for lung cancer among survivors of non-Hodgkin lymphoma

2015 ◽  
Author(s):  
Clara Lam ◽  
Rochelle Curtis ◽  
Graca Dores ◽  
Eric Engels ◽  
Neil Caporaso ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lung Cancer ◽  
Hodgkin Lymphoma ◽  
Non Hodgkin Lymphoma

Extra-nodal non-Hodgkin-lymphoma with an acneiform eruption: folliculotropic mycosis fungoides

2011 ◽  
Vol 87 (2) ◽  
pp. 189-190
Author(s):  
Patrick A. Oberholzer ◽  
Ivan Hegyi ◽  
Luca Borradori ◽  
Helmut Beltraminelli
Keyword(s):  
Hodgkin Lymphoma ◽  
Mycosis Fungoides ◽  
Non Hodgkin Lymphoma ◽  
Acneiform Eruption

Second Malignancies Among Elderly Multiple Myeloma Patients Exposed to Bortezomib and Other Treatments: An Analysis of the US SEER-Medicare Linked Database,

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 3972-3972
Author(s):  
Dina Gifkins ◽  
Megan McAuliffe ◽  
Amy Matcho ◽  
Jane Porter ◽  
Scott Chavers ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Hodgkin Lymphoma ◽  
Solid Tumors ◽  
Myeloid Leukemia ◽  
Lymphocytic Leukemia ◽  
Second Malignancy ◽  
Second Malignancies ◽  
Non Hodgkin Lymphoma ◽  
Equity Ownership ◽  
Medicare Database

Abstract Abstract 3972 Second hematologic malignancies have been found to occur at a higher rate among multiple myeloma patients compared to the general population. Although alkylating therapy has been suggested to play a role, the underlying causes remain largely unclear. Increased survival benefit has been documented with the introduction of novel agents over the past decade, and, as noted in other cancers, there may also be a higher occurrence of second malignancies in the era of novel therapies. Recently, data from Phase III studies suggest that patients treated with lenalidomide with prior exposure to melphalan may have an increased risk compared to placebo. However, the contribution of other specific agents has not been well characterized. Evaluation of second malignancies in clinical trial and product safety data for bortezomib has not revealed an increased incidence in bortezomib-treated patients. Additionally, our follow-up study of the VISTA clinical trial participants after 5 years showed no elevation in risk (San Miguel, et al. ASH 2011). To expand our current knowledge, we are conducting a population-based study using the NCI SEER-Medicare database (NCI SEER cancer registry linked with diagnostic and treatment claims data of Medicare beneficiaries) to evaluate bortezomib and other standard treatment exposures in relation to second malignancies subsequent to multiple myeloma. Using the NCI SEER-Medicare database, we identified all multiple myeloma patients with their first diagnosis between 1 Jan 2000 and 31 Dec 2007 aged 66 years or older. Exposure to chemotherapy was identified via Medicare claims, and second malignancies, defined as invasive cancers whose onset was after bortezomib-based therapy and occurring at least 2 months after the initial multiple myeloma diagnosis, were identified from the SEER registries. We identified the number of second malignancies among elderly patients with multiple myeloma and following bortezomib exposure; expanded multivariate analyses, adjusted for exposures, will be presented at the meeting. A total of 9,377 multiple myeloma patients were identified (median age 76 years; 50% males). During the study period, 2,285 (21%) patients had any documented exposure to bortezomib (with or without other treatments). Patients with bortezomib exposure had a median age of 73 years, and 55% were male. Among these 2,285 patients with bortezomib exposure, 33 patients (1.4%) developed a second malignancy (4 [0.2%] hematologic and 29 [1.3%] solid tumors) during the study period after their first documented bortezomib exposure. Hematologic tumors were non-Hodgkin lymphoma (n=3) and acute myeloid leukemia (n=1). Solid tumors were prostate (n=4), bladder (n=4), lung and bronchus (n=3), colon (excluding rectum) (n=3), breast (n=3), and other (n=12). Among the 7,092 multiple myeloma patients with no documented exposure to bortezomib, 320 (4.5%) developed a second malignancy (55 [0.8%] hematologic and 265 [3.7%] solid tumors) during the study period. Hematologic tumors were non-Hodgkin lymphoma (n=16), acute myeloid leukemia (n=7), chronic lymphocytic leukemia (n=2), acute lymphocytic leukemia (n=1), chronic myeloid leukemia (n=1), Hodgkin lymphoma (n=1), and other (n=27). Solid tumors were lung and bronchus (n=46), prostate (n=38), colon (excluding rectum) (n=33), melanoma (n=23), bladder (n=21), breast (n=17), and other (n=87). Based on more than 9,000 elderly multiple myeloma patients, we found a lower prevalence of second malignancies among persons exposed to bortezomib compared to those with no documented bortezomib exposure in our unadjusted analysis. To account for survival and adjust for other exposures, expanded analyses will be presented at the meeting, including standardized incidence ratios and calculations of absolute excess risk among patients exposed to bortezomib and other standard treatments compared to the general SEER population, cumulative incidence of second malignancy for each treatment group adjusting for death as a competing risk, and multivariate analyses to assess risk while adjusting for prior and concomitant treatments and other risk factors. Disclosures: Gifkins: Janssen Research & Development: Employment; Johnson & Johnson: Equity Ownership. McAuliffe:Millennium Pharmaceuticals, Inc.: Employment. Matcho:Janssen Research & Development: Employment; Johnson & Johnson: Equity Ownership. Porter:Millennium Pharmaceuticals, Inc.: Employment. Chavers:Janssen Research & Development: Employment; Johnson & Johnson: Equity Ownership. Ponsillo:Millennium Pharmaceuticals, Inc.: Employment. King:Janssen Research & Development: Employment; Johnson & Johnson: Equity Ownership. Desai:Janssen Research & Development: Employment; Johnson & Johnson: Equity Ownership. Cakana:Janssen Research & Development: Employment; Johnson & Johnson: Equity Ownership. Esseltine:Millennium Pharmaceuticals, Inc.: Employment; Johnson & Johnson: Equity Ownership.

Lymphomas

2019 ◽  
pp. 317-350
Author(s):  
Richard W Tsang ◽  
Mary K Gospodarowicz ◽  
Peter Hoskin
Keyword(s):  
Radiation Therapy ◽  
Hodgkin Lymphoma ◽  
Late Stage ◽  
Second Malignancies ◽  
Planning Techniques ◽  
Treatment Toxicity ◽  
Non Hodgkin Lymphoma ◽  
Lymphoma Treatment ◽  
Total Body

Chapter 16 discusses lymphomas, including discussion on nodal and extranodal non-Hodgkin lymphoma, and Hodgkin lymphoma. , treatment of early and late stage lymphomas, radiation therapy volume and dose, and planning techniques. It includes skin lymphomas and total body electron treatment, toxicity after radiotherapy for lymphoma, and second malignancies.

Unsuspected Synchronous Lung Cancer Unveiled on FDG PET After Chemotherapy for Non-Hodgkin Lymphoma

2008 ◽  
Vol 33 (2) ◽  
pp. 109-110 ◽  
Author(s):  
Yifan Zhang ◽  
Geming Li ◽  
Hongming Zhuang
Keyword(s):  
Lung Cancer ◽  
Hodgkin Lymphoma ◽  
Fdg Pet ◽  
Non Hodgkin Lymphoma ◽  
Synchronous Lung Cancer
Sign in / Sign up

Export Citation Format

Share Document